Clinical Research of UC-MSCs in the Treatment of Diabetic Nephropathy
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
Diabetic nephropathy (DN) is one of the most serious complications of diabetes and the
leading cause of end-stage chronic kidney disease. DN is a refractory disease with low
awareness, high incidence, and high disability. The incidence of DN can reach 30 to 40% after
20 years of diabetes, of which 5~10% of patients will progress to end-stage renal disease,
and epidemiological surveys predict that by 2030, DN will become the seventh leading cause of
death in the world. Currently, there are no effective drugs for treating DN. This clinical
trial is to inspect the safety and efficiency of human umbilical cord mesenchymal stem cells
(UC-MSCs) therapy for patients with DN.